This study, called EMERALD, is looking at how well radiotherapy (radiation treatment) alone works for women aged 60 or older with early-stage, low-risk breast cancer after they've had a lumpectomy (surgery to remove the tumor). Researchers want to see if this approach can control the cancer and how it affects your quality of life. To join, you must have been diagnosed with invasive breast cancer, be at least 60 years old, and have had breast-conserving surgery. Your tumor size must be 3cm or less, and your cancer should have specific low-risk markers (Ki-67 less than 20% and/or Oncotype score 0-10). The main goal is to check the safety and side effects of this treatment over about one year. The study is currently unclear on its recruitment status.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It is a Phase II trial and plans to enroll 300 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track safety and side effects for an average of one year. It will also look at long-term outcomes for up to 11 years through chart review or phone calls.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.